Incyte Announces Recipient of the Inaugural Incyte Ingenuity Award to Recognize Innovative Solutions that Address Needs in th...
September 09 2020 - 10:05AM
Business Wire
Massachusetts General Cancer Center awarded
$100,000 to launch a patient-centered mobile intervention app for
people with chronic graft-versus-host disease (GVHD)
Incyte (Nasdaq:INCY) today announced that Massachusetts General
Cancer Center is the recipient of the first Incyte Ingenuity Award,
an annual program that was created to support people living with
graft-versus-host disease (GVHD) by encouraging innovative and
novel solutions that address specific challenges facing the GVHD
community.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200909005229/en/
Massachusetts General Cancer Center has been awarded $100,000 to
implement its project, Horizon Mobile App for Patients with Chronic
GVHD – a patient-centered, multi-component mobile intervention app
that aims to improve the quality of life and care of patients with
chronic GVHD. The Incyte Ingenuity Award applications were reviewed
and evaluated by an independent judging panel consisting of Gerry
Cowden, Founder, Meredith Cowden Foundation, Shrina Duggal, Pharm.
D., BCOP, Clinical Pharmacy Specialist, and Navneet Majhail, M.D.,
Director, Blood and Marrow Transplant Program, Cleveland
Clinic.
The mobile app will consist of an educational game, which will
allow a patient character to navigate through a journey as they
cope with their chronic GVHD and monitor their progress. The
effectiveness of this app will be evaluated via a pilot program,
with consideration for a larger expansion.
“We are honored to receive the Incyte Ingenuity Award, which
will support our institution’s efforts to help advance care for
GVHD patients,” said Areej El-Jawahri, M.D., Director of the Bone
Marrow Transplant Survivorship Program, Massachusetts General
Cancer Center. “Specifically, this award will allow us to support
our chronic GVHD patients, who represent a vulnerable population
that experiences high degrees of physical and functional
limitations, impaired quality of life and significant psychological
distress, by developing an app focused on the essential
self-management and coping skills that are critical to improving
their lives.”
In its inaugural year, several nationally renowned cancer
research centers, teaching hospitals and patient advocacy groups
applied to receive the Incyte Ingenuity Award. Massachusetts
General Cancer Center was selected as this year’s award recipient
because the judges found it to be the most well-developed
application with a clear objective and realistic approach to
improving the GVHD patient journey.
“Incyte is honored to help advance this initiative from
Massachusetts General Cancer Center, which we believe has the
potential to have a significant impact on the experiences of GVHD
patients, their caregivers and their health care teams,” said Barry
Flannelly, Pharm. D., Executive Vice President and General Manager,
North America, Incyte. “The GVHD community’s positive response to
the Incyte Ingenuity Award program has been encouraging and
underscores the need for ongoing innovation and solutions, and we
look forward to seeing the results of this novel project as it is
executed over the next year.”
To read more about the winning initiative, and for more
information about the Incyte Ingenuity Award, visit
www.IncyteIngenuityAward.com.
About GVHD
GVHD is a condition that can occur after an allogeneic stem cell
transplant (the transfer of stem cells from a donor) where the
donated cells initiate an immune response and attack the transplant
recipient’s organs, leading to significant morbidity and mortality.
There are two major forms of GVHD, acute and chronic, that can
affect multiple organ systems including the skin, gastrointestinal
(digestive) tract, lung and liver.1
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical
company focused on finding solutions for serious unmet medical
needs through the discovery, development and commercialization of
proprietary therapeutics. For additional information on Incyte,
please visit Incyte.com and follow @Incyte.
References
- Leukemia & Lymphoma Society. "Graft-Versus-Host Disease
Facts." Available at:
https://www.lls.org/treatment/types-of-treatment/stem-cell-transplantation/graft-versus-host-disease.
Accessed June 2020.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200909005229/en/
Incyte Media Jenifer
Antonacci +1 302 498 7036 jantonacci@incyte.com
Kristen Griffiths +1 302 498 7012 kgriffiths@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jul 2023 to Jul 2024